Listed

Achieve Life Sciences, Inc.

ACHVNasdaqCIK 949858HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Net income−$74.8m, Q2 FY2026
Achieve Life Sciences, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m3.6Research and development, Q3 FY2023, three months to 2023-09-30$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure2.1Research and development, Q4 FY2023, three months to 2023-12-31$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-11, accession 0000950170-25-036831. Derived: 12-month figure less the 9-month figure.Report this figure2.8Research and development, Q1 FY2024, three months to 2024-03-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure5.1Research and development, Q2 FY2024, three months to 2024-06-30$5.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure7.6Research and development, Q3 FY2024, three months to 2024-09-30$7.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure7.3Research and development, Q4 FY2024, three months to 2024-12-31$7.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-11, accession 0000950170-25-036831. Derived: 12-month figure less the 9-month figure.Report this figure7.1Research and development, Q1 FY2025, three months to 2025-03-31$7.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure6.7Research and development, Q2 FY2025, three months to 2025-06-30$6.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure5.3Research and development, Q3 FY2025, three months to 2025-09-30$5.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figurenot reportednot reportednot reported
Operating income$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Interest expense$m0.8Interest expense, Q3 FY2023, three months to 2023-09-30$781.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure0.8Interest expense, Q4 FY2023, three months to 2023-12-31$787.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-28, accession 0000950170-24-038049. Derived: 12-month figure less the 9-month figure.Report this figure0.8Interest expense, Q1 FY2024, three months to 2024-03-31$813.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-09, accession 0000950170-24-056929.Report this figure0.8Interest expense, Q2 FY2024, three months to 2024-06-30$804.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-13, accession 0000950170-24-096193.Report this figure0.4Interest expense, Q3 FY2024, three months to 2024-09-30$366.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure0.2Interest expense, Q4 FY2024, three months to 2024-12-31$197.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figure0.2Interest expense, Q1 FY2025, three months to 2025-03-31$185.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure0.2Interest expense, Q2 FY2025, three months to 2025-06-30$191.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure0.2Interest expense, Q3 FY2025, three months to 2025-09-30$192.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure0.3Interest expense, Q4 FY2025, three months to 2025-12-31$251.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figure0.3Interest expense, Q1 FY2026, three months to 2026-03-31$274.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure0.3Interest expense, Q2 FY2026, three months to 2026-06-30$277.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(7.1)Net income, Q3 FY2023, three months to 2023-09-30−$7.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure(5.5)Net income, Q4 FY2023, three months to 2023-12-31−$5.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figure(6.5)Net income, Q1 FY2024, three months to 2024-03-31−$6.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure(8.5)Net income, Q2 FY2024, three months to 2024-06-30−$8.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure(12.5)Net income, Q3 FY2024, three months to 2024-09-30−$12.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure(12.4)Net income, Q4 FY2024, three months to 2024-12-31−$12.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figure(12.8)Net income, Q1 FY2025, three months to 2025-03-31−$12.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure(12.7)Net income, Q2 FY2025, three months to 2025-06-30−$12.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure(14.4)Net income, Q3 FY2025, three months to 2025-09-30−$14.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure(14.7)Net income, Q4 FY2025, three months to 2025-12-31−$14.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figure(10.2)Net income, Q1 FY2026, three months to 2026-03-31−$10.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure(74.8)Net income, Q2 FY2026, three months to 2026-06-30−$74.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure
Diluted EPS$ per share(0.34)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figurenot reported(0.26)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure(0.25)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure(0.36)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figurenot reported(0.37)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure(0.37)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure(0.28)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figurenot reported(0.19)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure(0.80)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure
Basic EPS$ per share(0.34)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figurenot reported(0.26)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure(0.25)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure(0.36)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figurenot reported(0.37)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure(0.37)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure(0.28)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figurenot reported(0.19)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure(0.80)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure

Balance sheet

Cash and equivalents$48.0m, Q2 FY2026
Shareholders' equity−$14.7m, Q2 FY2026
Achieve Life Sciences, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m19.9Cash and equivalents, Q3 FY2023, at 2023-09-30$19.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0000950170-23-062028.Report this figure15.5Cash and equivalents, FY2023, at 2023-12-31$15.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-11, accession 0000950170-25-036831.Report this figure66.4Cash and equivalents, Q1 FY2024, at 2024-03-31$66.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0000950170-24-056929.Report this figure14.8Cash and equivalents, Q2 FY2024, at 2024-06-30$14.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-13, accession 0000950170-24-096193.Report this figure9.5Cash and equivalents, Q3 FY2024, at 2024-09-30$9.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure12.8Cash and equivalents, FY2024, at 2024-12-31$12.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure13.0Cash and equivalents, Q1 FY2025, at 2025-03-31$13.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure51.9Cash and equivalents, Q2 FY2025, at 2025-06-30$51.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure31.9Cash and equivalents, Q3 FY2025, at 2025-09-30$31.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure20.9Cash and equivalents, FY2025, at 2025-12-31$20.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure28.1Cash and equivalents, Q1 FY2026, at 2026-03-31$28.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure48.0Cash and equivalents, Q2 FY2026, at 2026-06-30$48.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure
Current assets$m21.9Current assets, Q3 FY2023, at 2023-09-30$21.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062028.Report this figure17.0Current assets, FY2023, at 2023-12-31$17.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-11, accession 0000950170-25-036831.Report this figure67.7Current assets, Q1 FY2024, at 2024-03-31$67.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056929.Report this figure62.5Current assets, Q2 FY2024, at 2024-06-30$62.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0000950170-24-096193.Report this figure45.5Current assets, Q3 FY2024, at 2024-09-30$45.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure36.5Current assets, FY2024, at 2024-12-31$36.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure25.0Current assets, Q1 FY2025, at 2025-03-31$25.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure56.9Current assets, Q2 FY2025, at 2025-06-30$56.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure50.1Current assets, Q3 FY2025, at 2025-09-30$50.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure39.9Current assets, FY2025, at 2025-12-31$39.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure31.1Current assets, Q1 FY2026, at 2026-03-31$31.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure188Current assets, Q2 FY2026, at 2026-06-30$188.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure
Total assets$m24.3Total assets, Q3 FY2023, at 2023-09-30$24.3m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0000950170-23-062028.Report this figure19.4Total assets, FY2023, at 2023-12-31$19.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-11, accession 0000950170-25-036831.Report this figure70.0Total assets, Q1 FY2024, at 2024-03-31$70.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-056929.Report this figure64.8Total assets, Q2 FY2024, at 2024-06-30$64.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0000950170-24-096193.Report this figure47.9Total assets, Q3 FY2024, at 2024-09-30$47.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure38.6Total assets, FY2024, at 2024-12-31$38.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure27.4Total assets, Q1 FY2025, at 2025-03-31$27.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure58.9Total assets, Q2 FY2025, at 2025-06-30$58.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure52.0Total assets, Q3 FY2025, at 2025-09-30$52.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure41.8Total assets, FY2025, at 2025-12-31$41.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure33.1Total assets, Q1 FY2026, at 2026-03-31$33.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure190Total assets, Q2 FY2026, at 2026-06-30$190.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure
Current liabilities$m4.1Current liabilities, Q3 FY2023, at 2023-09-30$4.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062028.Report this figure20.8Current liabilities, FY2023, at 2023-12-31$20.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-11, accession 0000950170-25-036831.Report this figure20.6Current liabilities, Q1 FY2024, at 2024-03-31$20.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056929.Report this figure13.7Current liabilities, Q2 FY2024, at 2024-06-30$13.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0000950170-24-096193.Report this figure6.7Current liabilities, Q3 FY2024, at 2024-09-30$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure6.7Current liabilities, FY2024, at 2024-12-31$6.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure7.1Current liabilities, Q1 FY2025, at 2025-03-31$7.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure8.6Current liabilities, Q2 FY2025, at 2025-06-30$8.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure9.7Current liabilities, Q3 FY2025, at 2025-09-30$9.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure9.1Current liabilities, FY2025, at 2025-12-31$9.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure11.8Current liabilities, Q1 FY2026, at 2026-03-31$11.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure198Current liabilities, Q2 FY2026, at 2026-06-30$197.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure
Total liabilities$m20.3Total liabilities, Q3 FY2023, at 2023-09-30$20.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0000950170-23-062028.Report this figure20.8Total liabilities, FY2023, at 2023-12-31$20.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-11, accession 0000950170-25-036831.Report this figure20.6Total liabilities, Q1 FY2024, at 2024-03-31$20.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-056929.Report this figure22.5Total liabilities, Q2 FY2024, at 2024-06-30$22.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0000950170-24-096193.Report this figure16.5Total liabilities, Q3 FY2024, at 2024-09-30$16.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure17.7Total liabilities, FY2024, at 2024-12-31$17.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure17.1Total liabilities, Q1 FY2025, at 2025-03-31$17.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure17.3Total liabilities, Q2 FY2025, at 2025-06-30$17.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure18.4Total liabilities, Q3 FY2025, at 2025-09-30$18.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure20.3Total liabilities, FY2025, at 2025-12-31$20.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure22.4Total liabilities, Q1 FY2026, at 2026-03-31$22.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure205Total liabilities, Q2 FY2026, at 2026-06-30$205.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure
Shareholders' equity$m4.0Shareholders' equity, Q3 FY2023, at 2023-09-30$4.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure(1.4)Shareholders' equity, FY2023, at 2023-12-31−$1.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure49.5Shareholders' equity, Q1 FY2024, at 2024-03-31$49.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure42.3Shareholders' equity, Q2 FY2024, at 2024-06-30$42.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure31.4Shareholders' equity, Q3 FY2024, at 2024-09-30$31.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure20.9Shareholders' equity, FY2024, at 2024-12-31$20.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure10.3Shareholders' equity, Q1 FY2025, at 2025-03-31$10.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure41.7Shareholders' equity, Q2 FY2025, at 2025-06-30$41.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure33.6Shareholders' equity, Q3 FY2025, at 2025-09-30$33.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure21.5Shareholders' equity, FY2025, at 2025-12-31$21.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure10.7Shareholders' equity, Q1 FY2026, at 2026-03-31$10.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure(14.7)Shareholders' equity, Q2 FY2026, at 2026-06-30−$14.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure

Cash flow

Operating cash flow−$10.8m, Q2 FY2026
Capital expenditure$6.0k, Q4 FY2023
Achieve Life Sciences, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(5.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$5.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123375. Derived: 9-month figure less the 6-month figure.Report this figure(4.4)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figure(5.3)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure(4.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$4.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0000950170-25-104571. Derived: 6-month figure less the 3-month figure.Report this figure(10.4)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$10.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-268074. Derived: 9-month figure less the 6-month figure.Report this figure(9.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figure(11.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure(9.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$9.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344624. Derived: 6-month figure less the 3-month figure.Report this figure(11.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$11.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-268074. Derived: 9-month figure less the 6-month figure.Report this figure(18.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$18.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figure(6.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$6.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure(10.8)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$10.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344624. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reported0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$6.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-24, accession 0001193125-26-120690. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)93.51m, Q2 FY2026
Achieve Life Sciences, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares9.7Diluted shares (weighted), Q3 FY2022, three months to 2022-09-309,693,788 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0000950170-23-062028.Report this figure17.9Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3117,917,769 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-056929.Report this figure19.0Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3019,048,627 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0000950170-24-096193.Report this figure21.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3021,127,281 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123375.Report this figure25.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3125,048,134 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0000950170-25-069806.Report this figure34.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3034,318,709 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0000950170-25-104571.Report this figure34.4Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3034,355,050 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure34.7Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3134,685,072 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure34.7Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3034,685,072 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure51.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3051,017,662 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure53.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3153,381,989 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure93.5Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3093,510,544 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure

Shares outstanding: 102.90mShares outstanding, period not labelled, at 2026-08-11102,902,490 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure at Aug 11, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. Listed shows no prices and gives no investment advice.